Literature DB >> 9246699

Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.

T L Venables1, R D Newland, A C Patel, J Hole, M B Copeman, M L Turbitt.   

Abstract

BACKGROUND: Gastro-oesophageal reflux disease (GORD) is a frequent cause for consultation in general practice and is a chronically relapsing disease.
METHODS: This general practice study was a 6-month randomized, double-blind parallel-group placebo-controlled assessment of the efficacy and safety of continuous treatment with 10 mg omeprazole every morning after initial symptom control in 495 patients with GORD but without erosive oesophagitis.
RESULTS: On the basis of life-table estimates for cumulative relapse rates, patients in the placebo group (52%) were almost twice as likely as those in the omeprazole group (27%) to discontinue therapy before 24 weeks because of inadequate relief of heartburn or for other reasons including adverse events (all-patients-treated analysis, log rank test, P = 0.0001).
CONCLUSIONS: This study has shown that 10 mg omeprazole once daily is an effective and well-tolerated treatment strategy in general practice for the long-term management of symptoms of GORD in patients without erosive oesophagitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246699     DOI: 10.3109/00365529708996509

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  12 in total

Review 1.  Endoscopy-negative reflux disease.

Authors:  J P Galmiche; S B des Varannes
Journal:  Curr Gastroenterol Rep       Date:  2001-06

2.  Clinical outcomes after laparoscopic antireflux surgery in patients with and without preoperative endoscopic esophagitis.

Authors:  Ketan M Desai; Margaret M Frisella; Nathaniel J Soper
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

Review 3.  Assessment of reflux symptom severity: methodological options and their attributes.

Authors:  P Bytzer
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  Maintenance therapy of gastroesophageal reflux disease.

Authors:  Akihito Nagahara; Mariko Hojo; Daisuke Asaoka; Sumio Watanabe
Journal:  Clin J Gastroenterol       Date:  2010-02-19

5.  Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.

Authors:  Peter Wahlqvist; Ola Junghard; Andy Higgins; Jonathan Green
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 6.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 7.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Pilot study of on-demand therapy with pantoprazole 20mg for long-term treatment in patients with mild gastro-oesophageal reflux disease.

Authors:  Theo Scholten; Uwe Pustlauk; Peter Sander; Martina Bohuschke; Gudrun Gatz
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 9.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.